Anti gna13

The western blotting analysis was performed as previously published [16 (link)]. The following antibodies were used: anti-Her2 (Cell Signalling, catalogue #2242), anti-Flotillin-1 (Cell Signalling, catalogue #18634), anti-integrin beta 1 (Cell Signalling, catalogue #9699), anti-RAB10 (Cell Signalling, catalogue #8127), anti-PERP (Abcam, catalogue ab5986), anti-GNAS2 (Abcam catalogue #ab83735), and anti-GNA13 (catalogue #Abcam, ab128900). When lanes were removed from the western blot images, and separate parts of an image were joined together, a short vertical black line was used to indicate where the image was cut. Western blot signals were quantified using an Odyssey Imaging System-associated software v3.0 (LI-COR Biosciences) or the Quantity One software (Biorad).

Equal amounts of whole cell and tissue lysates were resolved by SDS-polyacrylamidegel electrophoresis (PAGE) and electrotransferred on a polyvinylidene difluoride (PVDF) membrane (Pall Corp., Port Washington, NY). The following primary antibodies were used: anti-GNA13 (Abcam, Cambridge, UK); anti-GAPDH, anti-GSK3β, anti-p-GSK3β, anti-AKT, anti-p-AKT, anti-ERK, anti-p-ERK, anti-c-Myc, anti-FOXO1, anti-p-FOXO1 (Cell signaling Technology, Beverly, MA).